| Carcinoma breast stage IV
Ixempra vs Orserdu
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Ixempra vs Orserdu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrserdu has a higher rate of injection site reactions vs Ixempra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orserdu but not Ixempra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ixempra
Orserdu
At A Glance
IV infusion
Every 3 weeks
Microtubule inhibitor (epothilone analog)
Oral
Daily
Estrogen receptor antagonist
Indications
- Carcinoma breast stage IV
- Locally advanced breast cancer
- Carcinoma breast stage IV
Dosing
Carcinoma breast stage IV, Locally advanced breast cancer (with capecitabine) 40 mg/m2 IV over 3 hours every 3 weeks; capecitabine 1000 mg/m2 twice daily for 2 weeks per cycle.
Carcinoma breast stage IV, Locally advanced breast cancer (single agent) 40 mg/m2 IV over 3 hours every 3 weeks.
Carcinoma breast stage IV 345 mg taken orally once daily with food until disease progression or unacceptable toxicity; dose reductions to 258 mg or 172 mg once daily for adverse reactions.
Contraindications
- Neutrophil count <1500 cells/mm3 or platelet count <100,000 cells/mm3
- History of severe hypersensitivity to agents containing Cremophor EL or its derivatives (e.g., polyoxyethylated castor oil)
- Combination with capecitabine in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN
—
Adverse Reactions
Most common (>=20%) Peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, musculoskeletal pain; in combination therapy also: palmar-plantar erythrodysesthesia, anorexia, abdominal pain, nail disorder, constipation.
Most common hematologic (>40%) Neutropenia, leukopenia, anemia, thrombocytopenia.
Serious Peripheral neuropathy, myelosuppression, hypersensitivity reactions, cardiac adverse reactions (myocardial infarction, arrhythmia, left ventricular dysfunction), sepsis, pneumonia, respiratory failure, acute hepatic failure.
Postmarketing Radiation recall.
Most common (>=10%) Musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, dyspepsia.
Serious Musculoskeletal pain, nausea.
Pharmacology
Ixabepilone is a semi-synthetic analog of epothilone B that binds directly to beta-tubulin subunits on microtubules, suppressing microtubule dynamic instability and blocking cells in the mitotic phase of the cell division cycle, leading to cell death.
Estrogen receptor antagonist that binds to ERalpha and inhibits 17beta-estradiol mediated cell proliferation through ERalpha protein degradation via the proteasomal pathway, with demonstrated antitumor activity in ESR1-mutated and CDK4/6 inhibitor-resistant ER+ HER2- breast cancer models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ixempra
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Orserdu
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ixempra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Orserdu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Ixempra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Orserdu
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IxempraView full Ixempra profile
OrserduView full Orserdu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.